NRX Pharmaceuticals, Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
NRx Pharmaceuticals received FDA approval of its Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine on October 30, 2026, ahead of the November 10 goal date. The drug removes benzethonium chloride (BZT), a toxic preservative banned from new drugs, and will be manufactured in the U.S. by Nephron Pharmaceuticals using modern blow-fill-seal technology. Ketamine has been on the FDA drug shortage list since 2018, and this approval addresses a critical supply gap for anesthesia and pain management.
Why this rating
Regulatory win opens new revenue stream for $57M market-cap company in shortage-driven market; material but execution/commercial success remains uncertain.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $2.33 ▲ 1.55% | at our read · unknown $2.29 | +10 min · unknown $2.35 ▲ 2.84% | +30 min · unknown $2.41 ▲ 5.24% | +1 hr pending | +4 hrs pending |
The stock had already moved -1.52% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.